Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2009

View Archived Issues

Karo Bio present update on drug development programs

Dienogest exhibits favorable safety profile in the long-term treatment of endometriosis

Phase I study results encourage further development of anesthetic PF-0713

EMEA committee informs Antigenics of negative opinion on MAA for Oncophage in RCC

Gilead reports results from third quarter of 2009

PSN-0041 displays enhanced antidepressant activity over native amylin in preclinical tests

Preclinical characterization of SEP-230864 presented by Sepracor

KB-099520 increases serotonergic activity and demonstrates antidepressant effects

IMO-3100 active in arthritis model, intended for clinical development

Naproxcinod efficacy similar to naproxen in knee osteoarthritis patients

Brain autoimmune mechanisms implicated in the pathogenesis of OCD / News in Context

Peregrine reports positive tumor response rate in phase II bavituximab trial

Aerie reports phase IIa results for ROCK inhibitor, AR-12286, in glaucoma

AcelRx presents results from phase II ARX-03 study

KemPharm commences phase I KP-106 trial in ADHD

Roche doses first patient in phase III subcutaneous Herceptin trial

TargeGen completes TG-101348 trial in patients with myelofibrosis

NexGenix awarded phase I grant for small-molecule Hsp90 compounds for glioma

Repligen licenses compounds for potential spinal muscular atrophy treatment

Merck and Schering-Plough receive European Commission clearance for merger

Aeolus drug protects gastrointestinal tract in acute radiation syndrome studies

CHMP recommends Boehringer's Micardis for CV morbidity in high CV risk patients

Onyx and Bayer initiate phase III trial of Nexavar in nonresponsive thyroid cancer

Pharmaxis commences pivotal bronchiectasis study with Bronchitol

CGRP antagonists for the treatment of migraine claimed by Merck & Co.

New glucokinase activators described by Astellas Pharma as antidiabetic agents

GlaxoSmithKline presents antiviral compounds for HCV infection

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...